Next Article in Journal
Current Melanoma Treatments: Where Do We Stand?
Next Article in Special Issue
The Prognostic Role of LRIG Proteins in Endometrial Cancer
Previous Article in Journal
Image-Guided Proton Therapy for Elderly Patients with Hepatocellular Carcinoma: High Local Control and Quality of Life Preservation
Article

Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)

1
Centre Léon Berard (CLB), 69008 Lyon, France
2
EORTC, Translational Research, 1200 Brussels, Belgium
3
Institut Bergonié, 33000 Bordeaux, France
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(2), 220; https://doi.org/10.3390/cancers13020220
Received: 27 November 2020 / Revised: 30 December 2020 / Accepted: 7 January 2021 / Published: 9 January 2021
(This article belongs to the Special Issue High Risk Gynecological Cancers)
Ovarian yolk sac tumors (OYSTs) are rare and specific therapeutic strategies are needed after the failure of platinum-based first-line and salvage regimens. This retrospective study included ten patients with OYST, including patients with relapsed disease and disease-free patients. Three patients (33.3%) harbored oncogenic mutations in KRAS, KIT and ARID1A, which may be used as a target. Our series shows that relapsed patients with molecular analysis had clinically relevant molecular alterations. Future research with dedicated trials and multicenter international collaborations are needed to demonstrate the efficacy of specific therapeutic strategies after failure of platinum-based first-line and salvage regimens.
Most patients with malignant ovarian germ cell tumors (MOGTCs) have a very good prognosis and chemotherapy provides curative treatment; however, patients with yolk sac tumors (OYSTs) have a significantly worse prognosis. OYSTs are rare tumors and promising results are expected with the use of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens. We initiated a project in collaboration with EORTC SPECTA, to explore the molecular characteristics of OYSTs. The pilot project used retrospective samples from ten OYST relapsed and disease-free patients. Each patient had a molecular analysis performed with FoundationOne CDx describing the following variables according to the Foundation Medicine Incorporation (FMI): alteration type (SNV, deletion), actionable gene alteration, therapies approved in EU (for patient’s tumor type and other tumor types), tumor mutational burden (TMB), and microsatellite instability (MSI) status. A total of 10 patients with OYST diagnosed between 2007 and 2017 had a molecular analysis. A molecular alteration was identified in four patients (40%). A subset of three patients (33.3% of all patients) harbored targetable oncogenic mutations in KRAS, KIT, ARID1A. Two patients at relapse harbored a targetable mutation. This retrospective study identifies clinically relevant molecular alterations for all relapsed patients with molecular analysis. Dedicated studies are needed to demonstrate the efficacy of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens and to explore the potential relationship of a molecular alteration and patient outcome. View Full-Text
Keywords: OYST; molecular characteristics; targetable mutation; patient outcome OYST; molecular characteristics; targetable mutation; patient outcome
Show Figures

Figure 1

MDPI and ACS Style

Hodroj, K.; Stevovic, A.; Attignon, V.; Ferraioli, D.; Meeus, P.; Croce, S.; Chopin, N.; Rossi, L.; Floquet, A.; Rousset-Jablonski, C.; Tredan, O.; Guyon, F.; Treilleux, I.; Rannou, C.; Morfouace, M.; Ray-Coquard, I. Molecular Characterization of Ovarian Yolk Sac Tumor (OYST). Cancers 2021, 13, 220. https://doi.org/10.3390/cancers13020220

AMA Style

Hodroj K, Stevovic A, Attignon V, Ferraioli D, Meeus P, Croce S, Chopin N, Rossi L, Floquet A, Rousset-Jablonski C, Tredan O, Guyon F, Treilleux I, Rannou C, Morfouace M, Ray-Coquard I. Molecular Characterization of Ovarian Yolk Sac Tumor (OYST). Cancers. 2021; 13(2):220. https://doi.org/10.3390/cancers13020220

Chicago/Turabian Style

Hodroj, Khalil, Aleksandra Stevovic, Valery Attignon, Domenico Ferraioli, Pierre Meeus, Sabrina Croce, Nicolas Chopin, Lea Rossi, Anne Floquet, Christine Rousset-Jablonski, Olivier Tredan, Frédéric Guyon, Isabelle Treilleux, Corinne Rannou, Marie Morfouace, and Isabelle Ray-Coquard. 2021. "Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)" Cancers 13, no. 2: 220. https://doi.org/10.3390/cancers13020220

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop